Alerts will be sent to your verified email
Verify Email
ASTRAZEN
Insufficient data
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
AstraZeneca Pharma India, a subsidiary of AstraZeneca Plc, focuses on delivering innovative medicines in cardiovascular, renal, metabolic diseases, oncology, and respiratory therapies.
Astrazeneca Pharma I major competitors are Wockhardt, Pfizer, Alembic Pharma, Eris Lifesciences, Jubilant Pharmova, Caplin Point Lab, Natco Pharma.
Market Cap of Astrazeneca Pharma I is ₹21,879 Crs.
While the median market cap of its peers are ₹18,502 Crs.
Astrazeneca Pharma I seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Jun Aug | Mar Jun Sep Dec | Jun | |||||||||||||||
| Investor Presentation | Mar Jun | Mar Jun Dec | Mar Jun Sep Dec | Jun Sep Dec | Dec | Mar | Dec | |||||||||||
| Conference Call | ||||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
